Background: Chronic hepatitis B virus (HBV) infection is a major public health concern affecting over 500 million people worldwide. HBV is a partially double stranded DNA virus that preferentially infects hepatocytes and causes acute hepatitis. While this acute hepatitis resolves in most patients, a subset of patients progress to chronic hepatitis with development of liver fibrosis. HBV shares several features with HIV that includes similar routes of transmission, development of chronic disease, and use of a reverse transcriptase enzyme to integrate in to the host genome. The latter feature is associated with the difficulties involved in eradicating HBV in chronically infected patients. Current treatment options for HBV include pegylated interferon alfa and nucleotide based therapy. Suppression of HBV replication is achieved in most treated patients, however, similar to HIV infection, discontinuation of therapy is associated with relapse of HBV viremia. Unlike HIV infection, both innate and adaptive immune responses have been associated with resolution of acute HBV infection and development of protective immunity in most adult patients exposed to HBV resulting in resolution of acute HBV infection. However, strategies to replicate this protective immunity in human subjects, which would enable them to stop antiviral therapy, have not yet been successful. Major reasons for our inability to cure HBV in chronically infected subjects include both viral and host factors. Viral factors such as a highly error prone replication system, presence of pre-core mutants, immune escape mutants and host factors that result in a lack of development of adaptive immune responses against HBV underscore the difficulties in our ability to boost HBV specific immunity in vivo. Recently, several strategies to eradicate HBV have been adopted that target the virus (potent directly acting antiviral agents, agents that target release of HBsAg), target innate immune system (toll-like receptor agonists), enhance antiviral immunity (therapeutic vaccinations) and target immunoregulatory mechanisms (PD-1, Tim-3). These approaches are promising, however, the safety profile of targeting key immunoregulatory mechanisms that may be vital for maintenance of physiological homeostasis of host immunity may need to be carefully evaluated. Conclusions: A combination of targeting the virus and boosting host immunity may be the ideal approach to eradicate HBV. The safety of such an approach chronic hepatitis B patients needs to be evaluated.